Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.
Original title: “BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine”
New therapy aims to tackle antibiotic resistance
Original title: “Qnovia licenses novel antimicrobial peptide”
In fact, the former lost tens of billions of dollars in market value following reports of a tie-up between the pharmaceutical giants.
Original title: “An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.”
Guido Oelkers will guide BioNTech’s ongoing transition into an oncology-focused biotech, while co-founder and longtime leader Ugur Sahin prepares to join a fledgling mRNA startup.
Original title: “BioNTech taps Sobi executive Oelkers as its next CEO”
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.
Original title: “Supernus, Individor merge to beef up brain drug portfolio”
BioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will take over as CEO in early 2027.
Original title: “BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech”
The hack is unlikely to affect Amgen’s financial reporting and other operations, nor does the pharma expect its ability to meet patient needs will be compromised.
Original title: “Amgen hit with cybersecurity breach, patient data affected”
As biologics, biosimilars and GLP-1s drive demand for sterile drug products, CMOs and CDMOs are investing in fill-finish, lyophilization, inspection and packaging capacity to keep pace with a dynamic injectable market.
Original title: “Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity”
The Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals’ antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling—and readjusting. BioSpace looks at five contenders and where they currently stand.
Original title: “5 companies advancing ATTR assets in the wake of Wainua’s fail”
After an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior motive” and “biased intentions.”
Original title: “Capricor CEO won’t rule out legal action against FDA after negative adcomm”
The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.
Original title: “Lilly and Resilience invest $750M in diabetes and obesity drug device supply”